Stay updated on Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page
- Check3 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check10 days agoChange DetectedThe Publications section now lists the Larkin et al. 2015 publication with an erratum, replacing the earlier entry; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedLocations section updated: added a general 'Locations' grouping and included CA, MA, NY, and TX; removed California/Massachusetts/New York/Texas locations. The footer revision changed to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.5%

- Check46 days agoChange DetectedThe page now displays Revision: v3.3.2. The previous Revision: v3.3.1 entry has been removed.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision: v3.3.1 was added and v3.2.0 was removed on the page, reflecting a minor update to the document metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedRemoved the government funding/operating status notice from the page. The study details and other content remain unchanged.SummaryDifference0.3%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.